Carl Icahn and his fights with management sure do make for entertaining news coverage, but investors shouldn't spend too much time analyzing how the antics are going to affect the share price.
In case you missed it, Icahn has been in a battle with Biogen Idec's
Things came to a close with Icahn claiming to have won two seats on the board and Biogen Idec saying that it's too early to say who's won the seats. The reality of the situation is that it doesn't really matter how many seats he won. Even if all four of his nominees won, that's not going to be enough to make many changes when the rest of the members on the 13-member board were nominated by the company. Icahn is in the same situation that he's in with Amylin Pharmaceuticals
That isn't to say that Icahn can't get anything done. As a large shareholder he was able to encourage the sale of MedImmune to AstraZeneca
There's nothing wrong with getting your kicks from watching dramas on CNBC instead of SOAPnet, just don't expect the results of the vote to affect Biogen Idec's long-term outcome.